Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Trial Profile

A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 May 2019 Planned End Date changed from 1 Apr 2019 to 31 Dec 2020.
    • 13 May 2019 Planned primary completion date changed from 1 Mar 2019 to 31 Dec 2019.
    • 04 Dec 2018 Results assessing overall survival in a subset of responders to the combination of Brentuximab Vedotin and Bendamustine in Heavily Treated Patients with Relapsed or Refractory HL, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top